Program to restrict use of i.v. fluconazole

American Journal of Health-System Pharmacy

Volumn 61, Issue 16, 2004, Pages 1695-1698

  Gallagher, Jason C ^a,b   Lee, Kimberly B ^b  

^a HAHNEMANN UNIVERSITY HOSPITAL   (United States)

^b VIRGINIA COMMONWEALTH UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

FLUCONAZOLE;

ARTICLE; CANDIDIASIS; DRUG BIOAVAILABILITY; DRUG COST; DRUG MONITORING; DRUG USE; HEALTH CARE QUALITY; HEALTH PROGRAM; HUMAN; INTERMETHOD COMPARISON; PRIORITY JOURNAL;

EID: 8344264509     PISSN: 10792082     EISSN: None     Source Type: Journal    
DOI: 10.1093/ajhp/61.16.1695     Document Type: Article

References (20)

1. Singh N. Trends in the epidemiology of opportunistic fungal infections: predisposing factors and the impact of antimicrobial use practices. Clin Infect Dis. 2001; 33:1692-6.
2. Dismukes WE. Introduction to antifungal drugs. Clin Infect Dis. 2000; 30:653-7.
3. Rex JH, Walsh TJ, Sobel JD et al. Practice guidelines for the treatment of candidiasis. Clin Infect Dis. 2000; 30:662-78.
4. Red book. Montvale, NJ: Medical Economics; 2002:308.
5. Debruyne D, Ryckelynck JP. Clinical pharmacokinetics of fluconazole. Clin Pharmacokinet. 1993; 24:10-27.
6. Debruyne D. Clinical pharmacokinetics of fluconazole in superficial and systemic mycoses. Clin Pharmacokinet. 1997; 33: 52-77.
7. Buijk SL, Gyssens IC, Mouton JW et al. Pharmacokinetics of sequential intravenous and enteral fluconazole in critically ill surgical patients with invasive mycoses and compromised gastro-intestinal function. Intensive Care Med. 2001; 27:115-21.
8. DeMuria D, Forrest A, Rich J et al. Pharmacokinetics and bioavailability of fluconazole in patients with AIDS. Antimicrob Agents Chemother. 1993; 37: 2187-92.
9. Nicolau DP, Crowe H, Nightingale CH et al. Bioavailability of fluconazole administered via a feeding tube in intensive care unit patients. J Antimicrob Chemother. 1995; 36:395-401.
10. Rosemurgy AS, Markowsky S, Goode SE et al. Bioavailability of fluconazole in surgical intensive care unit patients: a study comparing routes of administration. J Trauma. 1995; 39:445-7.
11. Seay RE, Larson TA, Toscano JP et al. Pharmacokinetics of fluconazole in immune-compromised children with leukemia or other hematologic diseases. Pharmacotherapy. 1995; 15:52-8.
12. Tett S, Moore S, Ray J. Pharmacokinetics and bioavailability of fluconazole in two groups of males with human immunodeficiency virus (HIV) infection compared with those in a group of males without HIV infection. Antimicrob Agents Chemother. 1995; 39:1835-41.
13. Zimmermann T, Yeates RA, Riedel KD et al. The influence of gastric pH on the pharmacokinetics of fluconazole: the effect of omeprazole. Int J Clin Pharmacol Ther. 1994; 32:491-6.
14. Ramirez JA, Vargas S, Ritter GW et al. Early switch from intravenous to oral antibiotics and early hospital discharge: a prospective observational study of 200 consecutive patients with community-acquired pneumonia. Arch Intern Med. 1999; 159:2449-54.
15. Paladino JA, Sperry HE, Backes JM et al. Clinical and economic evaluation of oral ciprofloxacin after an abbreviated course of intravenous antibiotics. Am J Med. 1991; 91:462-70.
16. Ahkee S, Smith S, Newman D et al. Early switch from intravenous to oral antibiotics in hospitalized patients with infections: a 6-month prospective study. Pharmacotherapy. 1997; 17:569-75.
17. Grasela TH Jr, Paladino JA, Schentag JJ et al. Clinical and economic impact of oral ciprofloxacin as follow-up to parenteral antibiotics. DICP. 1991; 25:857-62.
18. Burkiewicz JS, Kostiuk KA, Jacobs RA et al. Impact of an intravenous fluconazole restriction policy on patient outcomes. Ann Pharmacother. 2001; 35:9-13.
19. Pappas PG, Rex JH, Sobel JD et al. Guidelines for the treatment of candidiasis. Clin Infect Dis. 2004; 38:161-89.
20. Gross R, Morgan AS, Kinky DE et al. Impact of a hospital-based antimicrobial management program on clinical and economic outcomes. Clin Infect Dis. 2001; 33:289-95.